SEINE BIO · Research, evidence & your next steps
Longer-acting signaling. A distinct research story.
Early human CJC-1295 studies reported sustained growth-hormone and IGF-1 changes. Learn what makes the DAC modification distinctive and how hormone-marker results differ from proven health outcomes.
This catalog formulation is investigational, not an FDA approved treatment.
How CJC-1295 with DAC works
CJC-1295 is a GHRH analogue; the drug-affinity complex (DAC) modification prolongs its activity. The resulting hormone-marker changes are a pharmacologic finding, not an established wellness outcome.
Why it’s getting attention
Small randomized studies in healthy adults reported sustained GH and IGF-1 effects. They did not establish long-term anti-aging, muscle-growth or injury-healing benefit. FDA has identified safety concerns including increased heart rate and systemic vasodilatory reactions.
Protocol reference at a glance
Reference context, not your prescription. No established patient protocol was identified for this formulation. The chart summarizes research context, not directions for use.
| Stage | What to expect from the evidence |
|---|---|
| Research setting | Early human studies evaluated prolonged hormone responses after specified study injections. |
| Starting / loading phase | No validated routine-care starting or loading dose established for this exact formulation. |
| Standard dose / maximum | No validated standard patient dose or safe maximum established here. |
| Maintenance / cycles | No validated ongoing maintenance or cycling protocol identified. |
Presentation & administration
Published study injections do not provide an interchangeable consumer pen or nasal regimen. The DAC version is not interchangeable with the product marketed as ‘without DAC’.
Catalog presentation: Vial / Cartridge / Disposable Injection Pen. Listed strength options: 5 mg; 10 mg. One catalog unit is one selected presentation—not a box containing every pictured format. Total container content is not a personal dose, and an illustration does not verify an approved route or device.
Risks & common side effects
- Growth-hormone pathway stimulation calls for review of glucose control, fluid retention, headaches, joint symptoms and IGF-1 levels. These are clinical screening concerns, not a quantified side-effect profile for this formulation.
- Existing cancer, unexplained masses, pituitary disease, diabetes, pregnancy and other hormone treatments deserve specialist review. Do not stack agents or adjust doses to chase laboratory numbers.
Tell your clinician about new or persistent symptoms and other medicines. Changes to treatment should be clinician-directed.
Other options worth discussing
Diagnosis-led endocrine care and an approved treatment when medically indicated are more established than manipulating GH/IGF-1 for general wellness goals. “More established” does not mean risk-free or suitable for everyone; a clinician should compare benefits, contraindications and your preferences.
When to seek help
Significant swelling, severe headache, palpitations, fainting, marked thirst or a suspected allergic reaction needs prompt medical assessment.
Finished-product quality, concentration and route require verification. Review allergies, pregnancy, health conditions and other medicines with your clinician.
Do not wait for a portal reply in an emergency. Call 911 or seek emergency care for severe or rapidly worsening symptoms.
A few useful answers
Does a lasting hormone response mean lasting benefits?
No. Higher or longer-lasting hormone markers are not the same as better health outcomes.
Is it the same as the no-DAC version?
No. The modification changes pharmacology, and protocols cannot be transferred between them.
Does clinician authorization guarantee access?
No. Clinical appropriateness, lawful availability and a verified finished formulation must each be established. An Rx setting, luxury image or research-series label does not create regulatory approval.
Research & references
General information, not a prescription or a guarantee of results. Research and reference-label schedules do not replace instructions for your exact prescribed product. Clinical suitability and lawful availability require separate confirmation.
Make your next step an informed one.
Share what you want to improve, what you have already tried, and the questions you have about CJC-1295 with DAC. Your care team can help put the evidence and alternatives in context.
Sign-in may be required. This is not an emergency service or a guarantee that this product is available.